Welcome to our dedicated page for Adaptimmune Therapeutics Plc SEC filings (Ticker: ADAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptimmune Therapeutics plc (ADAP) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as an issuer with American Depositary Shares previously listed on The Nasdaq Capital Market. These filings include current reports on Form 8-K, annual and quarterly reports referenced in company communications, and other documents that outline Adaptimmune’s financial condition, strategic transactions and corporate governance developments.
Through its Form 8-K filings, Adaptimmune reports material events such as notices from Nasdaq regarding minimum bid price deficiencies and the Low Priced Stocks Rule, approval to transfer its listing to the Nasdaq Capital Market, and the Board’s decision to voluntarily delist its ADSs and deregister them under Section 12(b) of the Securities Exchange Act of 1934. Filings also describe the company’s intention to file a Form 25 to effect the delisting and a subsequent Form 15 to suspend its reporting obligations once eligibility criteria are met.
Other key SEC documents detail the Asset Purchase Agreement and related transaction by which Adaptimmune sold the assets and rights related to its TECELRA, lete-cel, afami-cel and uza-cel cell therapies to USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC. These filings outline the upfront cash consideration, potential milestone payments, assumed liabilities, and associated license and transition services agreements, as well as the use of proceeds to repay indebtedness under a Loan and Security Agreement with Hercules Capital, Inc.
Adaptimmune’s 8-K filings also cover restructuring actions and workforce reductions, executive leadership changes, and separation or consulting agreements with senior officers, providing detail on severance terms and responsibilities. Financial information referenced in these filings, including revenue, research and development expenses, selling, general and administrative expenses, net income or loss, and the non-GAAP Total Liquidity measure, can be compared with press release summaries for a fuller picture of the company’s performance.
Stock Titan enhances these SEC filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand listing status changes, asset sales, restructuring plans and liquidity disclosures. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while structured views make it easier to follow Adaptimmune’s transition from a Nasdaq-listed cell therapy company with commercial assets to an issuer focused on remaining preclinical programs and strategic alternatives.
Adaptimmune insider sales by a director reduced his indirect holdings to zero. Ali Behbahani, a director and manager of entities holding shares, reported two dispositions of Adaptimmune ordinary shares represented by ADSs. On 08/15/2025 he reported sale of 4,828,206 ordinary shares at a weighted average price of $0.011 per share, leaving 14,671,794 shares indirectly owned. On 08/18/2025 he reported sale of 14,671,794 ordinary shares at a weighted average price of $0.012 per share, resulting in zero indirect beneficial ownership. The filings state these ordinary shares were held as ADSs by NEA 16 and explain price ranges and ownership through NEA entities.
This Amendment No. 3 to the Schedule 13D updates prior filings by New Enterprise Associates-related reporting persons concerning Adaptimmune Therapeutics Plc ordinary shares. Collectively the reporting persons hold 4 Ordinary Shares (the "Firm Shares"), which the filing states represents 0% of the class based on 1,590,309,546 Ordinary Shares outstanding. The filing discloses shared voting and dispositive power over those 4 shares and identifies the funds, control entities and individual managers involved. The Amendment attaches Schedule A for recent transactions and cites Exhibit 1 (joint filing agreement) and Exhibit 3 (power of attorney).
EcoR1 Capital, Oleg Nodelman and an EcoR1 fund report joint beneficial ownership of Adaptimmune Therapeutics plc ordinary shares. The filing shows EcoR1 Capital and Mr. Nodelman each have shared voting and dispositive power over 66,000,000 ordinary shares (representing 4.2% of the class), while EcoR1 Capital Fund Qualified, L.P. holds shared power over 63,184,650 ordinary shares (representing 4.0% of the class). The shares are held through American Depositary Shares (11,000,000 ADS for EcoR1/ Nodelman; 10,530,775 ADS for the Qualified Fund), with each ADS representing six ordinary shares. Percentages are calculated using 1,590,309,546 ordinary shares outstanding as of August 11, 2025. The filing states the positions were acquired in the ordinary course of business and not to influence control.
Adaptimmune Therapeutics plc reports the departure of Chief Commercial Officer Cintia Piccina and outlines the terms of her separation.
On August 15, 2025, subsidiary Adaptimmune, LLC entered into a separation agreement after her employment ended on August 8, 2025 by reason of redundancy, with the agreement effective August 23, 2025. Ms. Piccina will receive a lump-sum severance of $473,800, equal to 12 months of her 2025 base salary, subject to deductions, in full satisfaction of the company’s Executive Severance Policy. Her market value options continued to vest through the separation date, and she may exercise vested options over 1,125,648 ordinary shares until January 30, 2032, with 12 months from the separation date to exercise any other market value options that vested by that date.
Form 144 notice for Adaptimmune Therapeutics plc (ADAP): A proposed sale of 13,829,778 American Depositary Receipts is being submitted for sale through J.P. Morgan Securities LLC on or about 08/15/2025 on NASDAQ. The form lists the issuer's total shares outstanding as 1,590,309,546 and reports an aggregate market value for the proposed sale of 981,914. The ADRs were acquired in private placements from the issuer on several dates between 09/23/2014 and 09/05/2018, with recorded quantities for each acquisition and cash as the nature of payment. No securities were reported sold by the filer in the past three months. The filer certifies they are not aware of undisclosed material adverse information.
Form 144 notice: The filer notified the sale of 3,250,000 American Depositary Receipts (ADRs) through J.P. Morgan Securities LLC with an approximate aggregate market value of $230,750, and an approximate sale date of 08/15/2025 on NASDAQ. The filing reports 1,590,309,546 ADRs outstanding. The securities were originally acquired in private placements from the issuer on 09/05/2018 (2,000,000 ADRs) and 01/22/2020 (1,250,000 ADRs), with payment in cash on the acquisition dates. The filer certifies they have no undisclosed material adverse information. The filing shows no securities sold by the seller in the past three months.
Adaptimmune Therapeutics plc has received a new Nasdaq warning that its American Depositary Shares risk delisting after an extended share price decline. The company had already been out of compliance with Nasdaq’s
On
Adaptimmune disclosure: Two Seas Capital entities and Sina Toussi report beneficial ownership of 135,484,206 ordinary shares of Adaptimmune, representing 8.5% of the outstanding share class. The holdings are held by Two Seas Global (Master) Fund LP and are represented by 22,580,701 American Depositary Shares. The filing states that Two Seas Capital has sole voting and sole dispositive power over these shares through its advisory and partnership roles; Two Seas Capital GP serves as general partner and Sina Toussi serves as Managing Member and chief investment officer. The 8.5% figure is calculated using a total of 1,590,309,546 shares outstanding.
Adaptimmune Therapeutics plc (ADAP) reported a six-month net loss of $77.9 million and used $101.4 million of cash in operating activities through June 30, 2025. Revenue for the six months was $20.96 million, down from $133.91 million in the prior-year period, reflecting lower development revenue. Cash and cash equivalents were $26.1 million at period end and total assets fell to $130.6 million from $246.0 million at year-end. The company carried an accumulated deficit of $1,171.9 million and negative stockholders' equity of $70.96 million.
After period end, Adaptimmune completed an asset sale of its TECELRA, letecel, afami-cel and uza-cel product assets to US WorldMeds for $55.0 million upfront, with up to $30.0 million in contingent milestone payments, and used part of the proceeds to repay all indebtedness to Hercules (payoff ~$29.1 million), terminating the loan. The company announced further workforce reductions of approximately 62% post-transaction and expects to incur $7–8 million of pre-tax severance and related costs. Management states cash will be sufficient to meet operating requirements for 12 months following this filing.
Adaptimmune Therapeutics plc announced second-quarter financial results for the period ended June 30, 2025 and provided a corporate update. The Form 8-K furnishes the companys press release as Exhibit 99.1 and states that the furnished information is not deemed "filed" for purposes of Section 18 and is not incorporated by reference except by specific reference.
The filing does not include the financial figures or operational details; the full press release attached as Exhibit 99.1 contains the detailed results and corporate update.